201. Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis
- Author
-
Yan Huang, Shiyang Kang, Yaxiong Zhang, Hongyun Zhao, Xue Hou, Li Zhang, Wenfeng Fang, Ting Zhou, Fangfang Gao, Zhihuang Hu, Tao Qin, Jin Sheng, Yuanyuan Zhao, Yunpeng Yang, Yang He, Ningning Zhou, Cong Xue, Shaodong Hong, Ying Tian, Shuxiang Ma, Yuxiang Ma, and Jianhua Zhan
- Subjects
0301 basic medicine ,Oncology ,erlotinib ,medicine.medical_specialty ,Lung Neoplasms ,Afatinib ,Network Meta-Analysis ,gefitinib ,afatinib ,NSCLC ,03 medical and health sciences ,0302 clinical medicine ,Gefitinib ,Carcinoma, Non-Small-Cell Lung ,EGFR-TKI ,Internal medicine ,Humans ,Medicine ,Adverse effect ,neoplasms ,Protein Kinase Inhibitors ,business.industry ,Cancer ,Prognosis ,medicine.disease ,Rash ,respiratory tract diseases ,ErbB Receptors ,030104 developmental biology ,Tolerability ,030220 oncology & carcinogenesis ,Meta-analysis ,Mutation ,Erlotinib ,medicine.symptom ,business ,Research Paper ,medicine.drug - Abstract
// Yaxiong Zhang 1, 2, 3, * , Jin Sheng 1, 2, 3, * , Yunpeng Yang 1, 2, 3, * , Wenfeng Fang 1, 2, 3 , Shiyang Kang 2, 3, 4 , Yang He 5 , Shaodong Hong 1, 2, 3 , Jianhua Zhan 1, 2, 3 , Yuanyuan Zhao 1, 2, 3 , Cong Xue 1, 2, 3 , Yuxiang Ma 1, 2, 3 , Ting Zhou 1, 2, 3 , Shuxiang Ma 1, 2, 3 , Fangfang Gao 1, 2, 3 , Tao Qin 1, 2, 3 , Zhihuang Hu 1, 2, 3 , Ying Tian 1, 2, 3 , Xue Hou 1, 2, 3 , Yan Huang 1, 2, 3 , Ningning Zhou 1, 2, 3 , Hongyun Zhao 1, 2, 3 , Li Zhang 1, 2, 3 1 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China 2 State Key Laboratory of Oncology in South China, Guangzhou, China 3 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 4 Department of Anesthesiology, Sun Yat-sen University Cancer Center, Guangzhou, China 5 Lau Luen Hung Private Medical Center, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China * These authors have contributed equally to this work Correspondence to: Li Zhang, e-mail: zhangli6@mail.sysu.edu.cn Keywords: EGFR-TKI, NSCLC, gefitinib, erlotinib, afatinib Received: January 21, 2016 Accepted: February 18, 2016 Published: February 25, 2016 ABSTRACT Background: To answer which epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the best choice for advanced non-small cell lung cancer (NSCLC) EGFR mutants. Results: 16 phase III randomized trials involving 2962 advanced NSCLC EGFR mutants were enrolled. Multiple treatment comparisons showed different EGFR-TKIs shared equivalent curative effect in terms of all outcome measures among the overall, chemo-naive and previously treated patients. Rank probabilities showed that erlotinib and afatinib had potentially better efficacy compared with gefitinib in both of the overall and chemo-naive patients. Potentially survival benefit of erlotinib was also observed in previously treated patients compared with gefitinib. Additionally, EGFR-TKI showed numerically greater survival benefit in 19 Del compared with chemotherapy, while it was opposite in 21 L858R. Furthermore, afatinib, erlotinib and gefitinib had high, moderate and low risk of rash & diarrhea, respectively, while the occurrence of elevated liver transaminase was more common in gefitinib. Methods: Data of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse events were extracted from included studies. Efficacy and toxicity of all included treatments were integrated by network meta-analyses. Conclusion: Our study indicated a high efficacy-high toxicity pattern of afatinib, a high efficacy-moderate toxicity pattern of erlotinib and a medium efficacy-moderate toxicity pattern of gefitinib. Recommended EGFR-TKI should be suggested according to patients’ tolerability and therapeutic efficacy in clinical practice. Moreover, the treatment for advanced EGFR-positive NSCLC might be different between 19 Del and 21 L858R.
- Published
- 2016